Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-301 with Tislelizumab and Bevacizumab in pMMR/non-MSI-H mCRC
NCT07244705Phase 2Recruiting
- Sponsor
- Anbogen Therapeutics
- Start
- Nov 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of imofinostat in colorectal cancer (CRC), sponsored by Anbogen Therapeutics. Started Nov 2025; status: recruiting.
02
Drugs
imofinostat
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07244705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07244705.